{"ATC Code":"C01BA03","Abbreviation":"","Aliases":["Dicorantil","Disopiramida","Isorythm","Ritmodan","Lispine","Rythmodan P","Searle 703","Disopyramidum","Dl-disopyramide","SC 7031"],"Biological Half-Life":"6.7 hours (range 4-10 hours)","CAS":"3737-09-5","ChEBI":"CHEBI:4657","ChEMBL":"CHEMBL517","ChemicalClasses":["amphetamine"],"Chirality":"racemic","Classes":["Sodium channel blocker"],"Dosing Info":[],"Drug Classes":"Breast Feeding; Lactation; Milk, Human; Antiarrhythmics","Drug Indication":"For the treatment of documented ventricular arrhythmias, such as sustained ventricular tachycardia, ventricular pre-excitation and cardiac dysrhythmias. It is a Class Ia antiarrhythmic drug.","DrugClasses":[],"EINECS":"223-110-2","EliminationHalfLife":"6.7 hours (range 4 to 10 hours)","European Community (EC) Number":"223-110-2","FDA Pharmacological Classification":"GFO928U8MQ","FullSalts":["Disopyramide phosphate"],"HMDB ID":"HMDB0014425","HeavyAtomCount":25,"Human Drugs":"Breast Feeding; Lactation; Milk, Human; Antiarrhythmics","IUPACName":"4-[di(propan-2-yl)amino]-2-phenyl-2-pyridin-2-ylbutanamide","InChI":"InChI=1S/C21H29N3O/c1-16(2)24(17(3)4)15-13-21(20(22)25,18-10-6-5-7-11-18)19-12-8-9-14-23-19/h5-12,14,16-17H,13,15H2,1-4H3,(H2,22,25)","InChIKey":"UVTNFZQICZKOEM-UHFFFAOYSA-N","MeSH Pharmacological Classification":"A class of drugs that inhibit the activation of VOLTAGE-GATED SODIUM CHANNELS. (See all compounds classified as Voltage-Gated Sodium Channel Blockers.)","Melting Point":"94.5-95 °C","MolecularFormula":"C\u003csub\u003e21\u003c/sub\u003eH\u003csub\u003e29\u003c/sub\u003eN\u003csub\u003e3\u003c/sub\u003eO","MolecularWeight":"339.5 g/mol","Opticalactivity":"( + / - )","Pharmacodynamics":"Disopyramide is an anti-arrhythmic drug indicated for the treatment of documented ventricular arrhythmias, such as sustained ventricular tachycardia that are life-threatening. At therapeutic plasma levels, disopyramide shortens the sinus node recovery time, lengthens the effective refractory period of the atrium, and has a minimal effect on the effective refractory period of the AV node. Little effect has been shown on AV-nodal and His-Purkinje conduction times or QRS duration. However, prolongation of conduction in accessory pathways occurs.","Physical Description":"Solid","PrevSalts":["phosphate"],"PubChemId":3114,"Record Description":["Disopyramide is a monocarboxylic acid amide that is butanamide substituted by a diisopropylamino group at position 4, a phenyl group at position 2 and a pyridin-2-yl group at position 2. It is used as a anti-arrhythmia drug. It has a role as an anti-arrhythmia drug. It is a monocarboxylic acid amide, a member of pyridines and a tertiary amino compound.","A class I anti-arrhythmic agent (one that interferes directly with the depolarization of the cardiac membrane and thus serves as a membrane-stabilizing agent) with a depressant action on the heart similar to that of guanidine. It also possesses some anticholinergic and local anesthetic properties.","Disopyramide is an Antiarrhythmic.","Disopyramide is an oral antiarrhythmic agent that has been in wide use for several decades. Long term disopyramide therapy is associated with a low rate of serum enzyme elevations and is a rare cause of clinically apparent acute liver injury.","Disopyramide is a class IA anti-arrhythmic agent with cardiac depressant property. Disopyramide blocks the fast sodium channel in normal cardiac cell membranes within atrial and ventricular tissues. This slows the rate and amplitude of phase 0 depolarization and thus prolongs the duration of the action potential, thereby reducing cell excitability and conduction velocity. Further, disopyramide directly decreases the rate of diastolic (phase 4) depolarization in cells with normal or augmented automaticity. Disopyramide also blocks potassium channel and results in prolonged QT interval, thus increases the effective refractory period. This agent also possesses anticholinergic property.","DISOPYRAMIDE is a small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1977 and is indicated for ventricular arrhythmia and cardiac arrhythmia and has 2 investigational indications. This drug has a black box warning from the FDA.","A class I anti-arrhythmic agent (one that interferes directly with the depolarization of the cardiac membrane and thus serves as a membrane-stabilizing agent) with a depressant action on the heart similar to that of guanidine. It also possesses some anticholinergic and local anesthetic properties.","See also: Disopyramide Phosphate (has salt form).","Disopyramide is a monocarboxylic acid amide that is butanamide substituted by a diisopropylamino group at position 4, a phenyl group at position 2 and a pyridin-2-yl group at position 2. It is used as a anti-arrhythmia drug. It has a role as an anti-arrhythmia drug. It is a monocarboxylic acid amide, a member of pyridines and a tertiary amino compound.","LiverTox|Cardiac|Anti-arrhythmic|Pyridine derivative"],"References":[{"Name":"Wikipedia","Urls":[{"Link":"https://en.wikipedia.org/wiki/Disopyramide","Name":"Disopyramide","Sub":false}]},{"Name":"Wikidata","Urls":[{"Link":"https://www.wikidata.org/wiki/Q425120","Name":"Disopyramide","Sub":false},{"Link":"https://www.wikidata.org/wiki/Q81988263","Name":"(-)-Disopyramide","Sub":true}]},{"Name":"DrugBank","Urls":[{"Link":"https://go.drugbank.com/drugs/DB00280","Name":"Disopyramide","Sub":false}]},{"Name":"PubChem","Urls":[{"Link":"https://pubchem.ncbi.nlm.nih.gov/compound/3114","Name":"Disopyramide","Sub":false},{"Link":"https://pubchem.ncbi.nlm.nih.gov/compound/156295","Name":"(+)-Disopyramide","Sub":true},{"Link":"https://pubchem.ncbi.nlm.nih.gov/compound/156294","Name":"(-)-Disopyramide","Sub":true}]},{"Name":"ChEMBL","Urls":[{"Link":"https://www.ebi.ac.uk/chembl/explore/compound/CHEMBL517","Name":"Disopyramide","Sub":false},{"Link":"https://www.ebi.ac.uk/chembl/explore/compound/CHEMBL8821","Name":"(+)-Disopyramide","Sub":true},{"Link":"https://www.ebi.ac.uk/chembl/explore/compound/CHEMBL269362","Name":"(-)-Disopyramide","Sub":true}]},{"Name":"ChEBI","Urls":[{"Link":"https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:4657","Name":"Disopyramide","Sub":false}]},{"Name":"Common Chemistry","Urls":[{"Link":"https://commonchemistry.cas.org/detail?cas_rn=3737-09-5","Name":"Disopyramide","Sub":false},{"Link":"https://commonchemistry.cas.org/detail?cas_rn=74464-84-9","Name":"(+)-Disopyramide","Sub":true},{"Link":"https://commonchemistry.cas.org/detail?cas_rn=74464-83-8","Name":"(-)-Disopyramide","Sub":true}]},{"Name":"HMDB","Urls":[{"Link":"https://hmdb.ca/metabolites/HMDB0014425","Name":"Disopyramide","Sub":false}]},{"Name":"KEGG","Urls":[{"Link":"https://www.kegg.jp/entry/C06965","Name":"Disopyramide","Sub":false}]},{"Name":"UNII","Urls":[{"Link":"https://gsrs.ncats.nih.gov/ginas/app/ui/substances/GFO928U8MQ","Name":"Disopyramide","Sub":false},{"Link":"https://gsrs.ncats.nih.gov/ginas/app/ui/substances/4HB8OU08NH","Name":"(+)-Disopyramide","Sub":true},{"Link":"https://gsrs.ncats.nih.gov/ginas/app/ui/substances/O14QWZ0EF7","Name":"(-)-Disopyramide","Sub":true}]},{"Name":"EPA DSSTox","Urls":[{"Link":"https://comptox.epa.gov/dashboard/chemical/details/DTXSID1045536","Name":"Disopyramide","Sub":false},{"Link":"https://comptox.epa.gov/dashboard/chemical/details/DTXSID301043597","Name":"(+)-Disopyramide","Sub":true}]}],"SMILES":"CC(C)N(CCC(C1=CC=CC=C1)(C2=CC=CC=N2)C(=O)N)C(C)C","Salts":["phosphate"],"SaltsAcidCount":[1],"SaltsAmineCount":[1],"SaltsUNII":["N6BOM1935W"],"Scheduling":[{"gov":"Brazil","schedule":"C1 substance"},{"gov":"United Kingdom","schedule":"prescription only substance"},{"gov":"United States","schedule":"prescription only substance"}],"Solubility":"4.93e-02 g/L","StereoisomerRacemic":"(RS)-Disopyramide","Stereoisomers":["(+)-Disopyramide","(-)-Disopyramide"],"StereoisomersUNII":["4HB8OU08NH","O14QWZ0EF7"],"StoreUNII":["GFO928U8MQ"],"StructureBase64":"<svg xmlns="http://www.w3.org/2000/svg" xmlns:xlink="http://www.w3.org/1999/xlink" height="70.252mm" version="1.2" viewBox="0 0 107.667 70.252" width="107.667mm">
      
    <desc>Generated by the Chemistry Development Kit (http://github.com/cdk)</desc>
      
    <g fill="#3050F8" stroke="#000000" stroke-linecap="round" stroke-linejoin="round" stroke-width=".7">
            
        <rect fill="#FFFFFF" height="71.0" stroke="none" width="108.0" x=".0" y=".0"/>
            
        <g class="mol" id="mol1">
                  
            <line class="bond" id="mol1bnd1" x1="106.629" x2="93.431" y1="46.346" y2="38.726"/>
                  
            <line class="bond" id="mol1bnd2" x1="93.431" x2="93.431" y1="38.726" y2="23.486"/>
                  
            <line class="bond" id="mol1bnd3" x1="93.431" x2="83.386" y1="38.726" y2="44.525"/>
                  
            <line class="bond" id="mol1bnd4" x1="77.079" x2="67.034" y1="44.525" y2="38.726"/>
                  
            <line class="bond" id="mol1bnd5" x1="67.034" x2="53.836" y1="38.726" y2="46.346"/>
                  
            <line class="bond" id="mol1bnd6" x1="53.836" x2="40.638" y1="46.346" y2="38.726"/>
                  
            <line class="bond" id="mol1bnd7" x1="40.638" x2="27.44" y1="38.726" y2="46.346"/>
                  
            <g class="bond" id="mol1bnd8">
                        
                <line x1="27.44" x2="14.236" y1="46.346" y2="38.717"/>
                        
                <line x1="25.002" x2="14.236" y1="47.753" y2="41.533"/>
                      
                <line class="hi" stroke="#3050F8" x1="14.236" x2="20.838" y1="38.717" y2="42.531499999999994"/>
            </g>
                  
            <line class="bond" id="mol1bnd9" x1="14.236" x2="1.038" y1="38.717" y2="46.337"/>
                  
            <g class="bond" id="mol1bnd10">
                        
                <line x1="1.038" x2="1.043" y1="46.337" y2="61.586"/>
                        
                <line x1="3.477" x2="3.481" y1="47.745" y2="60.178"/>
                      
            </g>
                  
            <line class="bond" id="mol1bnd11" x1="1.043" x2="14.246" y1="61.586" y2="69.214"/>
                  
            <g class="bond" id="mol1bnd12">
                        
                <line x1="14.246" x2="27.444" y1="69.214" y2="61.594"/>
                        
                <line x1="14.247" x2="25.006" y1="66.398" y2="60.187"/>
                      
            </g>
                  
            <line class="bond" id="mol1bnd13" x1="27.44" x2="27.444" y1="46.346" y2="61.594"/>
                  
            <line class="bond" id="mol1bnd14" x1="40.638" x2="30.842" y1="38.726" y2="27.051"/>
                  
            <g class="bond" id="mol1bnd15">
                        
                <line x1="30.842" x2="36.052" y1="27.051" y2="12.729"/>
                        
                <line x1="29.032" x2="33.279" y1="24.894" y2="13.219"/>
                      
                <line class="hi" stroke="#3050F8" x1="35.75098861881971" x2="33.447" y1="13.556463531912492" y2="19.89"/>
                <line class="hi" stroke="#3050F8" x1="35.56538212891597" x2="33.447" y1="14.066685441394512" y2="19.89"/>
                <line class="hi" stroke="#3050F8" x1="33.279" x2="31.155500000000004" y1="13.219" y2="19.0565"/>
            </g>
                  
            <line class="bond" id="mol1bnd16" x1="36.052" x2="26.245" y1="12.729" y2="1.053"/>
                  
            <g class="bond" id="mol1bnd17">
                        
                <line x1="26.245" x2="11.227" y1="1.053" y2="3.699"/>
                        
                <line x1="25.282" x2="13.037" y1="3.699" y2="5.856"/>
                      
            </g>
                  
            <line class="bond" id="mol1bnd18" x1="11.227" x2="6.017" y1="3.699" y2="18.02"/>
                  
            <g class="bond" id="mol1bnd19">
                        
                <line x1="6.017" x2="12.983" y1="18.02" y2="26.314"/>
                        
                <line x1="8.79" x2="14.85" y1="17.531" y2="24.746"/>
                      
                <line class="hi" stroke="#3050F8" x1="12.983" x2="9.5" y1="26.314" y2="22.167"/>
            </g>
                  
            <line class="bond" id="mol1bnd20" x1="30.842" x2="19.144" y1="27.051" y2="29.112"/>
                  
            <line class="bond" id="mol1bnd21" x1="40.638" x2="50.434" y1="38.726" y2="27.051"/>
                  
            <g class="bond" id="mol1bnd22">
                        
                <line x1="49.952" x2="62.016" y1="25.728" y2="27.855"/>
                        
                <line x1="49.529" x2="61.592" y1="28.13" y2="30.257"/>
                      
                <line class="hi" stroke="#FF0D0D" x1="62.016" x2="55.983999999999995" y1="27.855" y2="26.7915"/>
                <line class="hi" stroke="#FF0D0D" x1="61.592" x2="55.560500000000005" y1="30.257" y2="29.1935"/>
            </g>
                  
            <line class="bond" id="mol1bnd23" x1="50.434" x2="46.706" y1="27.051" y2="16.809"/>
                  
            <line class="bond" id="mol1bnd24" x1="80.232" x2="80.232" y1="50.196" y2="61.586"/>
                  
            <line class="bond" id="mol1bnd25" x1="80.232" x2="93.431" y1="61.586" y2="69.206"/>
                  
            <line class="bond" id="mol1bnd26" x1="80.232" x2="67.034" y1="61.586" y2="69.206"/>
                  
            <path class="atom" d="M82.173 48.795h-.72l-2.62 -4.066h-.029q.012 .239 .029 .596q.024 .357 .024 .732v2.738h-.565v-4.899h.714l2.608 4.054h.029q-.006 -.107 -.018 -.327q-.011 -.221 -.023 -.477q-.006 -.262 -.006 -.482v-2.768h.577v4.899z" id="mol1atm4" stroke="none"/>
                  
            <path class="atom" d="M17.765 32.146h-.72l-2.62 -4.066h-.029q.012 .239 .029 .596q.024 .357 .024 .732v2.738h-.565v-4.899h.714l2.608 4.054h.029q-.006 -.107 -.018 -.327q-.011 -.221 -.023 -.477q-.006 -.262 -.006 -.482v-2.768h.577v4.899z" id="mol1atm19" stroke="none"/>
                  
            <path class="atom" d="M67.702 29.695q-.0 .756 -.256 1.327q-.256 .566 -.757 .881q-.5 .316 -1.244 .316q-.756 -.0 -1.262 -.316q-.506 -.315 -.756 -.887q-.244 -.571 -.244 -1.333q.0 -.75 .244 -1.31q.25 -.566 .756 -.881q.506 -.316 1.274 -.316q.732 .0 1.232 .316q.501 .31 .757 .875q.256 .566 .256 1.328zM63.838 29.695q-.0 .922 .387 1.458q.393 .53 1.22 .53q.84 -.0 1.221 -.53q.387 -.536 .387 -1.458q-.0 -.929 -.387 -1.453q-.381 -.524 -1.209 -.524q-.833 .0 -1.226 .524q-.393 .524 -.393 1.453z" fill="#FF0D0D" id="mol1atm21" stroke="none"/>
                  
            <g class="atom" id="mol1atm22">
                        
                <path d="M47.162 15.18h-.72l-2.62 -4.066h-.029q.012 .238 .029 .595q.024 .358 .024 .733v2.738h-.565v-4.899h.714l2.608 4.054h.029q-.006 -.107 -.018 -.328q-.011 -.22 -.023 -.476q-.006 -.262 -.006 -.482v-2.768h.577v4.899z" stroke="none"/>
                        
                <path d="M40.214 15.18h-.619v-2.286h-2.512v2.286h-.613v-4.899h.613v2.071h2.512v-2.071h.619v4.899z" stroke="none"/>
                        
                <path d="M42.719 16.669h-1.943v-.3l.771 -.778q.222 -.222 .372 -.393q.154 -.175 .232 -.339q.079 -.168 .079 -.365q-.0 -.243 -.147 -.368q-.143 -.128 -.371 -.128q-.215 -.0 -.379 .075q-.161 .075 -.328 .207l-.193 -.243q.171 -.146 .393 -.246q.225 -.1 .507 -.1q.411 -.0 .65 .207q.239 .207 .239 .575q.0 .228 -.096 .432q-.093 .2 -.265 .396q-.167 .197 -.393 .418l-.614 .604v.018h1.486v.328z" stroke="none"/>
                      
            </g>
                
            <line class="hi" id="mol1bnd3" stroke="#3050F8" x1="83.386" x2="88.4085" y1="44.525" y2="41.6255"/>
            <line class="hi" id="mol1bnd4" stroke="#3050F8" x1="77.079" x2="72.0565" y1="44.525" y2="41.6255"/>
            <line class="hi" id="mol1bnd9" stroke="#3050F8" x1="14.236" x2="7.6370000000000005" y1="38.717" y2="42.527"/>
            <line class="hi" id="mol1bnd16" stroke="#3050F8" x1="36.052" x2="31.1485" y1="12.729" y2="6.891"/>
            <line class="hi" id="mol1bnd16" stroke="#3050F8" x1="36.052" x2="31.1485" y1="12.729" y2="6.891"/>
            <line class="hi" id="mol1bnd20" stroke="#3050F8" x1="19.144" x2="24.993" y1="29.112" y2="28.0815"/>
            <line class="hi" id="mol1bnd23" stroke="#3050F8" x1="46.706" x2="48.57" y1="16.809" y2="21.93"/>
            <line class="hi" id="mol1bnd23" stroke="#3050F8" x1="46.706" x2="48.57" y1="16.809" y2="21.93"/>
            <line class="hi" id="mol1bnd23" stroke="#3050F8" x1="46.706" x2="48.57" y1="16.809" y2="21.93"/>
            <line class="hi" id="mol1bnd24" stroke="#3050F8" x1="80.232" x2="80.232" y1="50.196" y2="55.891"/>
        </g>
          
    </g>
    
</svg>
","Title":"Disopyramide","UNII":"GFO928U8MQ","Wikidata":"Q425120","Wikipedia":"Disopyramide","XLogP":3.2}